You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Process development for manufacturing eCD4-Ig
SBC: EMMUNE INC Topic: NIAIDABSTRACTeCD4-Ig is an antibody-like therapeutic for HIV that was constructed by fusing CD4 domains 1 and 2, and an HIV coreceptor-mimetic sulfopeptide, to the N- and C-termini of the constant Fc region of an antibody. eCD4-Ig will join an emerging class of long-acting therapeutics for treating and preventing HIV infection. As a consequence of being built from parts of HIV’s receptors, eCD4-Ig ne ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease
SBC: APTUS BIOSCIENCES LLC Topic: NIADiagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild andmoderate Alzheimer’s disease Aptus Biosciences, LLCBharat Gawande SummaryToday, 6.2 million Americans are living with Alzheimer’s disease (AD), resulting in $355 billion in annual medical care costs. As the US population over age 65 grows, the number of Americans living with AD is expected to increase to ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Gesture-Powered Software Platform of Neurologic Music Therapy Games and Puzzles: To Stimulate Neuroplasticity and Prolong Functional Independence in Individuals Diagnosed with Alzheimer's Disease
SBC: Cowart Jr, John Sigure Topic: NIAAbstractThe inclusion of music therapy into a total treatment modality can be used to improve the cognitive, physical, emotional, and social outcomes of patients diagnosed with neurological aging disorders, such as Alzheimer’s Disease (AD). Moreover, the healing benefits of music therapy and music-based interventions may be optimized when the patient is actively engaged in the process of creatin ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of the Inspired Therapeutics NeoMate Mechanical Circulatory Support System for Neonates and Infants
SBC: INSPIRED THERAPEUTICS LLC Topic: NHLBIProject Summary/Abstract Up to 14,000 children in the US are hospitalized with heart failure (HF)-related conditions each year with a mortality rate of 7-15%. Heart transplant is the gold standard of therapy, but the mortality rate while on the waiting list is 5-39%; thus, use of mechanical circulatory support (MCS) devices plays an important role in supporting cardiovascular function in this chal ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
PET Probes for Senescence Detection in Brain
SBC: Senotrac Biotechnology LLC Topic: NIAPROJECT SUMMARYAround 50 million people worldwide are suffering from Alzheimer’s disease (AD) and related dementias, and AD is observed primarily in aged people. Current diagnosis of AD relies primarily on observations of declines in mental and cognitive functions, when irreversible brain damage occurs. Positron emission tomography (PET) tracers for early diagnosis of AD have been developed via ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Protection of donor kidneys with synchronization modulation electric field (SMEF)
SBC: WR Biotech, LLC Topic: 400The goals of this Phase II application: 1) determine the translational significance of the i-SMEF (improved Synchronization Modulation Electric Field) in a preclinical animal model using adult Yorkshire pigs with kidney autotransplantation; and 2) determine the optimal parameters of the i-SMEF in protection against ischemic injury of the donor kidneys during cold storage and improvement of the tra ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Joyuus: A Web-based Tool for Postpartum Care Self-care to Address the Complex Needs of Underserved Women
SBC: JOYUUS, LLC Topic: 100PROJECT SUMMARY/ABSTRACT In the United States, the postpartum period is a critical time for both maternal and child health; the US maternal mortality rate is the highest among other developed, high-income countries. More than half of all maternal deaths occur postpartum, from one day to one year after birth.1-9 There are vast racial and ethnic disparities in maternal mortality and severe morbidity ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
STING Activators as Therapy for Cancer
SBC: STINGINN, LLC Topic: 102PROJECT SUMMARY The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This signaling process is largely governed by STING (stimulator o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Adipokine-enriched brown adipocytes for treating polycystic ovary syndromes
SBC: BioRestorative Therapies, Inc. Topic: NICHDAbstract Polycystic ovary syndromes (PCOS) affect 6-18% of reproductive age female, representing the most common endocrine disease in this population. PCOS causes gynecological, dermatologic and metabolic comorbidities, and also imposes long-term risks of diabetes mellitus type 2 (T2D), cardiovascular diseases (CVD) and psychiatric problems including severe depression. PCOS is related to complex h ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse
SBC: MYOSIN THERAPEUTICS INC. Topic: NIDAPROJECT SUMMARY In 2018, over 1 million people in the U.S. qualified as having a methamphetamine (METH) use disorder and rates of METH use are surging, largely in response to the opioid epidemic. METH use disorder is a chronic condition for which there are currently no FDA-approved medications. The only treatment options available are behavioral modification therapies, which have limited efficacy, ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health